What component is added to an ICS and LABA to create a triple therapy inhaler for very severe asthma?
Answer
Long-Acting Muscarinic Antagonist (LAMA)
When asthma severity progresses to a point where ICS and LABA combination therapy is insufficient for adequate control, a step up to triple therapy may be necessary. Triple therapy involves combining the foundational anti-inflammatory agent (ICS) and the long-acting bronchodilator (LABA) with an additional agent to further enhance bronchodilation and airway stability. This third essential component is the Long-Acting Muscarinic Antagonist (LAMA). Specific examples of LAMAs mentioned include drugs such as tiotropium, aclidinium, or glycopyrronium, providing a broader spectrum of long-term airway opening mechanisms.
Related Questions
What is the primary goal of a preventer inhaler in long-term asthma treatment?When is adjusting preventative treatment strongly indicated for an asthma patient?Which ICS medication is listed as a mono-therapy preventer, sometimes having a brown casing?What is the most common bronchodilator paired with an Inhaled Corticosteroid (ICS) in combination inhalers?What component is added to an ICS and LABA to create a triple therapy inhaler for very severe asthma?What specific regulatory warning has been linked to the Leukotriene Modifier drug Montelukast?Approximately how long may it take for ICS therapy to manifest its maximum protective effect through consistent daily use?What key feature defines Maintenance and Reliever Therapy (MART) regarding the inhaler used?What device is highly recommended for use with Pressurised Metered Dose Inhalers (MDIs) to improve lung delivery?What is the most effective preventative measure against local side effects like oral thrush from steroid inhalers?